 Home > Active Ingredient News > Drugs Articles > More than 10 biopharmaceutical companies have completed a new round of financing. What therapeutic areas are they targeting?

More than 10 biopharmaceutical companies have completed a new round of financing. What therapeutic areas are they targeting?

 Last Update: 2022-08-20
 Source: Internet
 Author: User

Tags

1 4 dilution

palo alto company

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Since August, innovative drug R&D companies in the Chinese biopharmaceutical field have ushered in a lot of financing progress.

Oncolytic viral drugs, antibody/nuclide conjugated drugs, cell therapy products, agonistic antibodies

Conway Bio

Established: 2018

Financing round: A+ round

On August 10, Kangwei (Guangzhou) Biotechnology Co.

The exclusive investment by SDIC Ventures is mainly used to accelerate the clinical trials of multiple projects in the R&D pipeline of Conway Bio.

Focusing on the development of new anti-tumor "first-in-class" and "best-in-class" immunotherapy drugs TLR7 agonist CAN1012 was approved for clinical use in China

Nucleus

Established: 2021

Financing round: Unknown round

On August 10, Crystal Nucleus Biomedical Technology (Nanjing) Co.

Jointly completed by Gaorong Capital, VI Venture, Lichen Capital, and old shareholder Kaitai Capital to accelerate the development of several innovative targeted nuclear drugs under Crystal Nucleobiology to the clinical stage

Crystal Nucleus is a biopharmaceutical company focusing on the research and development of nuclide-conjugated drugs.

Focus on the research and development of nuclide-conjugated drugs and has established multiple product pipelines in the field of oncology, including small molecule and peptide products

perpetual biology

Established: 2021

Financing round: Angel round

On August 8, Zhongshan Hengdong Bio-Pharmaceutical Co.

Led by Zhongshan Health Technology Industry Base Investment Management Co.

Committed to using the unique agonist antibody screening, optimization and evaluation core technology platform to develop agonist antibody drugs with class 1 new drug potential The fastest product will be submitted for new drug clinical trial application (IND) in 2023

Yijierike

Established: 2021

Financing rounds: Angel round and Pre-A round

On August 7, Yijie Like (Shanghai) Biotechnology Co.

Morningside Ventures, Xicheng Jinrui, Sany Innovation and Taiyu Investment jointly participated in the trial of Yijielike's own core epigenetic editing technology in non-human primates

Yijielike is a biotechnology company dedicated to using unique epigenetic regulation technology to treat a variety of diseases.

Committed to using unique epigenetic regulation technology to treat a variety of diseases Has established a pipeline of multiple candidate products, covering ophthalmology, neurodegenerative diseases, metabolic and rare diseases, etc.

Fann Bio

Established: 2016

Financing round: Pre-A round

On August 3, Guangzhou Fanen Biotechnology Co.

Led by Huafang Capital for IND filing and Phase 1 clinical trials of multiple cell therapy products of Generic Biopharmaceuticals

Founded in 2016, Fann Bio was co-founded by a team led by Dr.

Mainly engaged in the development of solid tumor immunotherapy drugs and related businesses The first cell therapy product (new drug) has been developed and has now entered the clinical research stage

Kangwanda Pharmaceutical

Established: 2009

Funding round: new round

On August 2, Hangzhou Kangwanda Pharmaceutical Technology Co.

Dongheng Industrial Group, Huafang Capital and Blue Mountain Investment will jointly participate in the clinical research of a new generation of oncolytic virus pipeline products and the development of follow-up guided virus products

Kangwanda Pharmaceutical was established in July 2009.

Covers adenovirus, poxvirus and herpes simplex virus

Viterilon

Established: 2017

Financing round: B round

On August 2, Sironax announced the completion of its Series B financing, raising a total of US$200 million

Led by Yunfeng Fund and Gaorong Capital for clinical development of RIPK1 inhibitors

Founded in 2017, Vitareilon is dedicated to exploring and developing innovative drugs for the treatment of aging-related degenerative diseases worldwide

Committed to exploring and developing innovative drugs for the treatment of aging-related degenerative diseases worldwide Dr.
Xiaodong Wang, Dr.
Zhiyuan Zhang, RIPK1 inhibitor SIR0365 is in phase 1 clinical trial

Anaerobic organisms

Established: 2019

Financing round: A round

On August 1, Anaerobic Bio announced that it has completed a 100 million yuan Series A financing, jointly led by Daotong Investment and Chengdu Science and Technology Venture Capital, and followed by Chuangdong Investment and Zhongxi Fund
.
This round of financing will be mainly used for talent team building, phase 2 clinical trials of live bacteria drugs, pipeline research and development of candidate drugs, and construction of bacterial drug production platforms
.

Daotong Investment Chengdu Science and Technology Venture Capital

Anaerobic was established in 2019, the founder is Dr.
Cheng Lei
.
The company focuses on the research and development of innovative drugs for human microbial flora.
Relying on the Key Laboratory of Anaerobic Microorganisms of the Ministry of Agriculture, it has built a high-throughput screening platform for anaerobic microorganisms with independent intellectual property rights, and constructed a human anaerobic microorganism covering many places in China.
Microbial strain library, including thousands of species
.
The Class 1 innovative biological drug "Vaginal Lactobacillus Liver Capsules" (code-named KAL-001) independently developed by anaerobic organisms is obtained from thousands of Lactobacillus strains through screening and evaluation
.
The product under study has obtained clinical trial approval for two indications of bacterial vaginosis and postmenopausal atrophic vaginitis in China, and is expected to submit an IND in the United States in 2022
.

Focus on the development of innovative drugs for human microflora "Vaginal use of Lactobacillus quadruple viable capsules" for bacterial vaginosis and postmenopausal atrophic vaginitis

Sisio Ai

Established: 2021

Financing round: Pre-A round

On August 2, Western Europe Ai (Hangzhou) Biopharmaceutical Co.
, Ltd.
(hereinafter referred to as "West Western Ai") announced the successful completion of the Pre-A round of financing
.
This round of financing was led by PricewaterhouseCoopers, and the funds raised will be used to accelerate the preclinical development and clinical application of the company's new drug CA1001 for the treatment of ischemic stroke
.

A new drug CA1001 for the treatment of ischemic stroke

Xixiou Ai was jointly introduced and established in December 2021 by Puhua Capital and Hangzhou Bay Area Shuchuang Technology, and assumed the functions of the group company CCOA Therapeutics in the Asia-Pacific region and the headquarters in China
.
Xixiouai focuses on the research and development of innovative drugs for cardiovascular and cerebrovascular diseases, cancer metastasis, rare diseases and hemorrhagic diseases, and its core project is CA1001
.
The results of animal experiments have proved that the drug has a fast onset of action, is highly safe, and has a synergistic effect with the combined application of plasminogen activator (tPA) and mechanical thrombectomy, which can significantly improve the efficiency of tPA thrombolysis or mechanical thrombectomy and reduce the The dose of tPA can avoid cerebral hemorrhage, expand the treatment time window, prevent reinfarction, and have multi-dimensional effects such as treating reperfusion injury and reducing mortality
.

Focusing on the development of innovative drugs for cardiovascular and cerebrovascular diseases, cancer metastasis, rare diseases and bleeding diseases can significantly improve the efficiency of tPA thrombolysis or mechanical thrombectomy, reduce the dosage of tPA, avoid cerebral hemorrhage, expand the treatment time window, and prevent recurrence.
infarction

Gerber Bio

Established: 2021

Financing round: A+ round

On August 1, Gerber Bio announced the completion of a $22 million A+ round of financing
.
This round of financing was led by Qiming Venture Partners, with participation from Eli Lilly Asia Fund and Kaitai Capital
.
Gerber Biosciences focuses on the research and development of targeted protein degradation drugs
.
The company has raised nearly $90 million since its launch in March 2021
.
The completed A+ round of financing will help Gerber Biotech to establish a research and development pipeline and further upgrade its protein-degrading drug development platform
.

Qiming Venture Partners, Eli Lilly Asia Fund and Cathay Capital Partners

Gerber Bio is a biotechnology company focusing on the research and development of innovative small molecule protein degradation drugs.
The founder and CEO of the company is Dr.
Lu Gang
.
At present, two molecular glue drugs with "best-in-class" potential in Gerber's product pipeline for the treatment of relapsed/refractory hematological tumors have entered the preclinical research stage, and the IND application is expected to be submitted in early 2023
.
In addition, the company has three potential "first-in-class" protein degraders for the treatment of solid tumors or inflammatory diseases that are about to enter the lead compound optimization stage
.

Focus on the development of small molecule innovative protein degradation drugs Two molecular glue drugs with "best-in-class" potential for the treatment of relapsed/refractory hematological tumors

Original Creatures

Established: 2015

Financing round: B round

On August 1, Yuanqi Bio announced the completion of the B round of financing with a total amount of more than 120 million US dollars.
This round of financing was jointly led by Qiming Venture Capital and Quanchuang Capital.
The new investors Shanghai Science and Technology Fund, Jianyi Capital (formerly Sinopharm Capital) ), Suzhou Fund, Boquan Capital and some international investment funds joined the investment, and the original shareholder C&D Emerging Investment continued to increase its holdings
.
According to Yuanqi Bio's press release, this round of financing will be mainly used to promote the development and commercialization of the company's more than ten tumor cell therapy product pipelines that have undergone full proof-of-concept (POC), and continue to improve the company's independent innovation technology platform construction.
As well as the planning and construction of future commercial production bases
.

Qiming Venture Partners has more than ten full proof-of-concept (POC) tumor cell therapy product pipelines

Yuanqi Bio was established in 2015 and is committed to the development of tumor cell immunotherapy products.
The chairman and CEO of the company is Dr.
Yang Huanfeng
.
In terms of product development progress, Ori-C101, the company's first self-developed CAR-T product targeting GPC3 for the treatment of advanced liver cancer, has submitted a clinical trial application in China.
Phase clinical study
.

CAR-T product targeting GPC3 for the treatment of advanced liver cancer GPRC5D CAR-T product

Tongyi Medicine

Established: 2016

Financing round: B round

On August 1, Tongyi Pharmaceutical announced the completion of its Series B financing
.
This round of financing was led by Huimei Capital, followed by Yuanfeng Capital, ABC International, Yicun Capital, etc.
The original shareholders such as Tonghe Yucheng also actively supported
.
Tongyi Medicine was established in 2016 with Dr.
Huang Baohua as its founder and CEO.
The company is committed to the development of innovative tumor-targeted dual-ligand drug conjugates (Bi-XDC)
.
Funds from this financing will be mainly used for the clinical development of Tongyi Medicine's Bi-XDC pipeline, including the China pivotal registration Phase 2 clinical study of CBP-1008, and the Sino-US Phase 1/2 clinical study of CBP-1018
.

Huimei Capital Tumor Targeted Dual Ligand Drug Conjugate (Bi-XDC)

Based on the self-developed dual-target ligand-drug conjugation technology platform, Tongyi Medicine has developed Bi-XDC, an innovative drug type.
It has the physical and chemical characteristics of small molecular weight, well-defined structure, easy synthesis and quality control, and is expected to overcome the The druggability barrier of a variety of molecules with good activity, opening up new avenues for drug development
.
Among them, CBP-1008 is the first Bi-XDC drug developed by the company, which targets the folate receptor (FRα) and transient receptor potential channel V subfamily 6 (TRPV6) receptors expressed on the surface of tumor cells, respectively.
Entering a pivotal registration Phase 2 clinical trial by the end of 2022
.
CBP-1018 is the second Bi-XDC drug developed by the company, and one of its targets is prostate-specific membrane antigen (PSMA)
.

Folate receptor (FRα) transient receptor potential channel V subfamily 6 (TRPV6) receptor

In addition to the above-mentioned companies, other drug R&D companies also completed financing in August.
Due to limited space, this article will not introduce them one by one
.
It is hoped that with the help of capital, these biopharmaceutical companies can speed up the development of drug candidates and bring new treatment options to patients as soon as possible
.

References

[1] Anaerobic Bio has completed 100 million yuan Series A financing, led by Daotong Investment and other institutions.
Retrieved Aug 01, 2022, from

[1] Anaerobic Bio has completed 100 million yuan Series A financing, led by Daotong Investment and other institutions.
Retrieved Aug 01, 2022, from [2]Family in the Bay Area｜West Western Europe Ai Biopharmaceutical completed nearly 100 million yuan of Pre-A round of financing.
Retrieved Aug 02, 2022, from https://mp.
weixin.
qq.
com/s/b7y_Yv3uBjGIeUEwE0QRJA

[2]Family in the Bay Area｜West Western Europe Ai Biopharmaceutical completed nearly 100 million yuan of Pre-A round of financing.
Retrieved Aug 02, 2022, from https://mp.
weixin.
qq.
com/s/b7y_Yv3uBjGIeUEwE0QRJA

[3] July | PricewaterhouseCoopers.
Retrieved Aug 01, 2022, from https://mp.
weixin.
qq.
com/s/RmNT1nDnBx7mYpleMqC_dA

[4]Portfolio | Tongyi Medicine completed the B round of financing and accelerated the world's first key registration phase II clinical trial of dual-ligand conjugated drugs.
Retrieved Aug 1, 2022.
From https://mp.
weixin.
qq.
com/s /w1ZOsDGV38t0U-G_S-if4A

[5]Company news: Conwanda's new round of financing and the introduction of strategic partners reached.
Retrieved Aug 02, 2022, from

[5]Company news: Conwanda's new round of financing and the introduction of strategic partners reached.
Retrieved Aug 02, 2022, from [6] Viterilon Announces Completion of $200 Million Series B Financing.
Retrieved Aug 02, 2022, from

[6] Viterilon Announces Completion of $200 Million Series B Financing.
Retrieved Aug 02, 2022, from [7] [First Release] Fineimmu completed nearly 100 million yuan of Pre-A round of financing, exclusive interview with founder Professor Zhou Penghui.
Retrieved Aug 02, 2022, from

[7] [First Release] Fineimmu completed nearly 100 million yuan of Pre-A round of financing, exclusive interview with founder Professor Zhou Penghui.
Retrieved Aug 02, 2022, from [8] Yijielike completed the angel round and Pre-A round of financing of more than 100 million yuan to accelerate the development of next-generation gene therapy.
Retrieved Aug 07, 2022, from https://mp.
weixin.
qq.
com/s/ nKPo1PPPtYy9weYh01nKNQ

[8] Yijielike completed the angel round and Pre-A round of financing of more than 100 million yuan to accelerate the development of next-generation gene therapy.
Retrieved Aug 07, 2022, from https://mp.
weixin.
qq.
com/s/ nKPo1PPPtYy9weYh01nKNQ

[9] Kangwei Bio completed the A+ round of financing of over 100 million yuan, with the exclusive investment of SDIC Ventures.
Retrieved Aug 07, 2022, from https://mp.
weixin.
qq.
com/s/vb_VwEVZCPG0uA4Z6kXbvQ

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.